
BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
EU top diplomat Kallas arrives in Kiev to commemorate Bucha massacre - 2
Tasting America: An Excursion Through Darling Cheap Food Brands - 3
Little Italy Mercato brings fresh food and community to downtown San Diego - 4
Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips - 5
Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
Exclusive-Head of Pemex's production arm to step down in coming days, sources say
Nitty gritty Manual for Picking Agreeable Tennis shoes
April's full moon decides the date of Easter — here's how it works
ADHD drugs work, but not the way experts thought
Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
Illegal entries into Germany halve over two years, border police say
Changing Negative Cash Mentalities: Enabling Your Monetary Excursion
Europe: 4 Urban communities for a Paramount Social Experience













